このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Clearside Biomedical マネジメント

マネジメント基準チェック /24

Clearside Biomedical'sの CEO はGeorge Lasezkayで、 Apr2019年に任命され、の在任期間は 5.17年です。の年間総報酬は$ 1.54Mで、 35.6%給与と64.4%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.51%を直接所有しており、その価値は$ 451.66K 。経営陣と取締役会の平均在任期間はそれぞれ2年と5年です。

主要情報

George Lasezkay

最高経営責任者

US$1.5m

報酬総額

CEO給与比率	35.6%
CEO在任期間	5.2yrs
CEOの所有権	0.5%
経営陣の平均在職期間	2yrs
取締役会の平均在任期間	5yrs

経営陣の近況

Recent updates

Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Nov 06

We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Jun 24

Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Nov 12

Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

Aug 11

Clearside Biomedical Q2 2022 Earnings Preview

Aug 08

Clearside Biomedical: A Pivotal 2022 Ahead

Apr 13

Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play

Dec 22

Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business

Sep 30

Clearside's Value Proposition Is Far From Clear

Aug 07

We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth

Jun 17

Clearside Biomedical climbs after positive results from early-stage wet AMD trial

Jun 15

Clearside Biomedical resubmits eye treatment XIPERE NDA

May 03

If You Had Bought Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago You'd Have Earned 45% Returns

Feb 16

Clearside Biomedical's early-stage wet AMD study gets underway

Jan 12

Trade Alert: Bradford Whitmore At Clearside Biomedical, Inc. (NASDAQ:CLSD), Has Just Spent US$1m Buying 11% More Shares

Jan 12

Clearside Bio drops 11% on launch of $12M direct offering

Jan 06

Clearside Biomedical: SCS Microinjector Platform With Significant Upside

Jan 05

CEO報酬分析

Clearside Biomedical の収益と比較して、George Lasezkay の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$35m
Dec 31 2023	US$2m	US$547k	-US$32m
Sep 30 2023	n/a	n/a	-US$37m
Jun 30 2023	n/a	n/a	-US$36m
Mar 31 2023	n/a	n/a	-US$35m
Dec 31 2022	US$2m	US$532k	-US$33m
Sep 30 2022	n/a	n/a	-US$5m
Jun 30 2022	n/a	n/a	-US$2m
Mar 31 2022	n/a	n/a	US$83k
Dec 31 2021	US$2m	US$516k	US$376k
Sep 30 2021	n/a	n/a	-US$25m
Jun 30 2021	n/a	n/a	-US$23m
Mar 31 2021	n/a	n/a	-US$23m
Dec 31 2020	US$1m	US$503k	-US$18m
Sep 30 2020	n/a	n/a	-US$14m
Jun 30 2020	n/a	n/a	-US$18m
Mar 31 2020	n/a	n/a	-US$18m
Dec 31 2019	US$1m	US$385k	-US$31m
Sep 30 2019	n/a	n/a	-US$49m
Jun 30 2019	n/a	n/a	-US$67m
Mar 31 2019	n/a	n/a	-US$82m
Dec 31 2018	US$150k	n/a	-US$83m
Sep 30 2018	n/a	n/a	-US$78m
Jun 30 2018	n/a	n/a	-US$72m
Mar 31 2018	n/a	n/a	-US$65m
Dec 31 2017	US$167k	n/a	-US$59m

報酬と市場: Georgeの総報酬 ($USD 1.54M ) は、 US市場 ($USD 678.50K ) の同規模の企業の平均を上回っています。

報酬と収益: Georgeの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

George Lasezkay (72 yo)

5.2yrs

在職期間

US$1,538,627

報酬

Dr. George M. Lasezkay, Pharm D, & J.D. has been Chief Executive Officer at Clearside BioMedical, Inc. since March 2020, serves as President since March 1, 2020 and served as its Interim Chief Executive Of...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
George Lasezkay	President	5.2yrs	US$1.54m	0.51% $ 463.1k
Charles Deignan	Chief Financial Officer	12.4yrs	US$854.41k	0.45% $ 408.3k
Thomas Ciulla	Chairman of Scientific Advisory Board	5.7yrs	US$749.87k	0% $ 0
Jenny Kobin	Head of Investor Relations	no data	データなし	データなし
Rick McElheny	Senior Vice President of Corporate Development & Alliance Management	1.8yrs	データなし	データなし
Rafael Andino	Senior Vice President of Engineering & Manufacturing	1.4yrs	データなし	データなし
Susan Coultas	Chief Clinical Officer	2yrs	データなし	データなし
Ngai Hang Chong	Chief Medical Officer	less than a year	データなし	0.085% $ 76.8k
Leslie Zacks	Secretary	no data	データなし	データなし

2.0yrs

平均在職期間

59yo

平均年齢

経験豊富な経営陣: CLSDの経営陣は経験豊富であると考えられます ( 2年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
George Lasezkay	President	6.8yrs	US$1.54m	0.51% $ 463.1k
Thomas Ciulla	Chairman of Scientific Advisory Board	1.3yrs	US$749.87k	0% $ 0
Christy Shaffer	Independent Director	12.4yrs	US$86.08k	0.0059% $ 5.3k
Benjamin Yerxa	Independent Director	2.3yrs	US$88.58k	0.024% $ 21.7k
Jeffrey Edwards	Independent Director	5.8yrs	US$88.58k	0% $ 0
Clay Thorp	Independent Chair of the Board	12.4yrs	US$96.08k	0.054% $ 49.0k
Carl Regillo	Member of Scientific Advisory Board	4.2yrs	データなし	データなし
William Humphries	Independent Director	12.4yrs	US$91.71k	0.068% $ 61.8k
David Boyer	Member of Scientific Advisory Board	4.2yrs	データなし	データなし
Nancy Hutson	Independent Director	4.2yrs	US$85.46k	0.12% $ 112.5k
Richard Croarkin	Independent Director	8.3yrs	US$91.08k	0% $ 0
David Brown	Member of Scientific Advisory Board	4.2yrs	データなし	データなし

5.0yrs

平均在職期間

63yo

平均年齢

経験豊富なボード: CLSDの取締役会は経験豊富であると考えられます ( 5年の平均在任期間)。

Clearside Biomedical マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Clearside Biomedical, Inc., Annual General Meeting, Jun 20, 2024

Insider recently bought US$130k worth of stock

Clearside Biomedical, Inc Appoints Anthony S. Gibney to its Board of Directors

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Chief Medical Advisor-Retina notifies of intention to sell stock

Clearside Biomedical, Inc. Executive Changes, Effective February 17, 2023

Recent updates

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Clearside Biomedical, Inc. to Report Q1, 2024 Results on May 09, 2024

Clearside Biomedical, Inc., Annual General Meeting, Jun 20, 2024

Insider recently bought US$130k worth of stock

Clearside Biomedical, Inc Appoints Anthony S. Gibney to its Board of Directors

New minor risk - Market cap size

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Clearside Biomedical, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Clearside Biomedical, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

Clearside Biomedical, Inc. has filed a Follow-on Equity Offering.

Clearside Biomedical, Inc. Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Consensus revenue estimates increase by 464%

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Clearside Biomedical, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

Clearside Biomedical Receives Non-Compliance Notice from Nasdaq

Consensus revenue estimates increase by 362%

New major risk - Revenue and earnings growth

New major risk - Negative shareholders equity

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Clearside Biomedical, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation At the American Society of Retina Specialists 41st Annual Scientific Meeting

Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of Its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema

We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Clearside Biomedical, Inc. Opens Enrollment in Odyssey Phase 2B Clinical Trial of Cls-Ax (Axitinib Injectable Suspension) in Wet AMD

Consensus revenue estimates decrease by 57%

Consensus revenue estimates increase by 100%, EPS downgraded

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Chief Medical Advisor-Retina notifies of intention to sell stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 9.4% to US$5.80

Clearside Biomedical, Inc. Executive Changes, Effective February 17, 2023

Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD

High number of new directors

Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Price target increased to US$7.50

Clearside Biomedical, Inc. Announces Positive Results in Safety, Durability and Biologic Effect in Oasis Phase 1/2A Clinical Trial of Suprachoroidal CLS-AX (axitinib Injectable Suspension) in Wet AMD Patients

Clearside Biomedical, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

Clearside Biomedical Q2 2022 Earnings Preview

Clearside Biomedical, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Clearside Biomedical Completes Dosing in Oasis Phase 1/2A Clinical Trial of CLS-AX in Wet AMD Patients

Clearside Biomedical, Inc. Appoints Susan Coultas as Chief Clinical Officer

Price target decreased to US$9.00

Consensus revenue estimates fall by 91%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Clearside Biomedical, Inc., Annual General Meeting, Jun 22, 2022

High number of new directors

Clearside Biomedical: A Pivotal 2022 Ahead

Bausch + Lomb and Clearside Biomedical, Inc. Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Clearside Biomedical, Inc. Appoints Benjamin R. Yerxa to Its Board of Directors

Clearside Biomedical, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Clearside Biomedical’s Suprachoroidal Injection Platform Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conference

Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play

Price target decreased to US$10.40

Third quarter 2021 earnings released: US$0.082 loss per share (vs US$0.052 loss in 3Q 2020)

Independent Director exercised options to buy US$215k worth of stock.

Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business

Clearside Biomedical Announces Completion of Dosing in Cohort 2 of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.13 loss in 2Q 2020)

Consensus revenue estimates increase to US$24.9m

Clearside's Value Proposition Is Far From Clear

マネジメント基準チェック /24